Press coverage about Selecta Biosciences (NASDAQ:SELB) has trended somewhat positive on Sunday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Selecta Biosciences earned a news impact score of 0.13 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.9832887159276 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Insider Buying: Selecta Biosciences, Inc. (SELB) Director Purchases 57,598 Shares of Stock (americanbankingnews.com)
- SELECTA BIOSCIENCES,INC. (NASDAQ:SELB) Files An 8-K Regulation FD Disclosure (4-traders.com)
- Selecta Biosciences, Inc. (SELB) Insider Acquires $186,200.00 in Stock (americanbankingnews.com)
- Timothy C. Barabe Buys 5,000 Shares of Selecta Biosciences, Inc. (SELB) Stock (americanbankingnews.com)
Selecta Biosciences (NASDAQ SELB) traded up $0.89 during trading hours on Friday, reaching $10.23. The company’s stock had a trading volume of 476,993 shares, compared to its average volume of 320,295. Selecta Biosciences has a 52-week low of $8.70 and a 52-week high of $28.00. The company has a debt-to-equity ratio of 0.32, a current ratio of 9.48 and a quick ratio of 9.48.
TRADEMARK VIOLATION NOTICE: “Selecta Biosciences (SELB) Given Daily News Sentiment Rating of 0.13” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/11/19/selecta-biosciences-selb-given-daily-news-sentiment-rating-of-0-13.html.
In other news, Director Timothy A. Springer purchased 57,598 shares of Selecta Biosciences stock in a transaction on Tuesday, November 14th. The stock was purchased at an average price of $9.27 per share, with a total value of $533,933.46. Following the transaction, the director now directly owns 461,349 shares in the company, valued at approximately $4,276,705.23. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Werner Cautreels purchased 20,000 shares of Selecta Biosciences stock in a transaction on Monday, November 13th. The shares were purchased at an average cost of $9.31 per share, with a total value of $186,200.00. Following the transaction, the insider now owns 321,203 shares in the company, valued at $2,990,399.93. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 82,598 shares of company stock valued at $766,983 and have sold 355,658 shares valued at $6,955,732. Corporate insiders own 41.90% of the company’s stock.
About Selecta Biosciences
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.